Biovie Inc Total Assets
Biovie Inc total assets. Based on the latest financial reports, Biovie Inc (BIVI) holds total assets worth $14.25 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BIVI stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Biovie Inc (2013–2026)
Total assets of Biovie Inc from 2013 to 2026. This chart illustrates how Biovie Inc's total assets have evolved over time, based on quarterly financial data. See Biovie Inc stock quote for real-time trading data and today's change.
Biovie Inc - Asset Composition Analysis
Biovie Inc Total Assets Breakdown (June 2026)
Biovie Inc total assets breakdown as of June 2026. Biovie Inc's total assets of $14.25 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.0% |
| Accounts Receivable | $2.15 Million | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $345.71 Billion | 2.4% |
Asset Composition Trend (2013–2026)
This chart illustrates how Biovie Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Biovie Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biovie Inc's current assets represent 95.7% of total assets in 2026, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 63.0% of total assets in 2026, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 2.4% of total assets.
Biovie Inc Competitors by Total Assets
Key competitors of Biovie Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Biovie Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.59 | 9.10 | 16.34 |
| Quick Ratio | 3.59 | 9.10 | 16.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.85 Million | $18.42 Million | $19.33 Million |
Biovie Inc - Advanced Valuation Insights
This section examines the relationship between Biovie Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.58 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 66089921.7% |
| Total Assets | $14.25 Trillion |
| Market Capitalization | $14.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biovie Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biovie Inc's assets grew by 66089921.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biovie Inc (2013–2026)
The table below shows the annual total assets of Biovie Inc from 2013 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $14.25 Trillion | +66089921.71% |
| 2025-06-30 | $21.56 Million | -14.46% |
| 2024-06-30 | $25.21 Million | -28.19% |
| 2023-06-30 | $35.10 Million | +74.52% |
| 2022-06-30 | $20.11 Million | +232.65% |
| 2021-06-30 | $6.05 Million | +190.16% |
| 2020-06-30 | $2.08 Million | -19.05% |
| 2019-06-30 | $2.57 Million | +18.34% |
| 2018-06-30 | $2.18 Million | -7.98% |
| 2017-06-30 | $2.36 Million | -13.05% |
| 2016-06-30 | $2.72 Million | +909.04% |
| 2015-06-30 | $269.48K | -19.04% |
| 2014-06-30 | $332.86K | -34.18% |
| 2013-06-30 | $505.70K | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Be… Read more